Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmanogepix in Adult Patients With Invasive Mold Infections
NCT06925321Phase 3Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2025
- Primary completion
- Feb 2028
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of fosmanogepix (3 cohorts), sponsored by Basilea Pharmaceutica. Primary endpoint: Day 42 all-cause mortality rate. Started Aug 2025; status: recruiting.
02
Drugs
fosmanogepix
Beyond the preview
Go deeper on NCT06925321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925321.